# KALA BIO, Inc.: overview KALA · Nasdaq · CIK 1479419 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/kala.md) · [Financials](/companies/kala/financials.md) · [Filings](/companies/kala/filings.md) · [Insiders](/companies/kala/insiders.md) Latest reported revenue: [$0](/filings/0001558370-24-004326.md) for Q4 FY2022, three months to 2022-12-31, from the 10-K filed Mar 29, 2024 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001558370-24-004326). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.93)](/filings/0001104659-25-113927.md) | not reported | [(70.49)](/filings/0001104659-26-062397.md) | [(85.64)](/filings/0001104659-26-098783.md) | [(1.07)](/filings/0001104659-25-113927.md) | not reported | [(0.14)](/filings/0001104659-26-062397.md) | [(21.32)](/filings/0001104659-26-098783.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [11.2](/filings/0001558370-23-002746.md) | [3.9](/filings/0001558370-24-004326.md) | [0.0](/filings/0001558370-25-004081.md) | [0.0](/filings/0001104659-26-043782.md) | [0.0](/filings/0001104659-26-043782.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(1158.8%)](/filings/0001558370-23-002746.md) | [(2099.3%)](/filings/0001558370-24-004326.md) | not reported | not reported | not reported | | Net margin | % | [(1268.7%)](/filings/0001558370-23-002746.md) | [(1151.6%)](/filings/0001558370-24-004326.md) | not reported | not reported | not reported | | Diluted EPS | $ per share | [(108.32)](/filings/0001558370-23-002746.md) | [(29.48)](/filings/0001558370-24-004326.md) | [(17.35)](/filings/0001558370-25-004081.md) | [(10.15)](/filings/0001104659-26-043782.md) | [(3.31)](/filings/0001104659-26-043782.md) | | Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/kala/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $381.7k | 220,623 | | New +220,623 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $251.1k | 145,152 | | New +145,152 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $175.4k | 101,396 | | New +101,396 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $123.8k | 71,542 | | New +71,542 | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $72.0k | 41,606 | | New +41,606 | | [Qube Research & Technologies Ltd](/funds/1729829.md) | 2026-06-30 | $19.2k | 11,073 | | New +11,073 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $18.9k | 10,921 | | New +10,921 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $15.7k | 9,057 | | New +9,057 | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $1.1k | 616 | | New +616 | | [BARCLAYS PLC](/funds/312069.md) | 2026-06-30 | $1.1k | 608 | | New +608 | ## Recent filings [All 674 filings](/companies/kala/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-24 | 20:10 ET | [DEF 14A](/filings/0001829126-26-010384.md) | Proxy statement, period 2026-11-03 | 0001829126-26-010384 | | 2026-09-10 | 21:24 ET | [8-K](/filings/0001829126-26-009999.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001829126-26-009999 | | 2026-09-09 | 21:06 ET | [8-K](/filings/0001829126-26-009946.md) | 5.08 Item not in the standard list; 8.01 Other events | 0001829126-26-009946 | | 2026-08-28 | 10:45 ET | [8-K](/filings/0001829126-26-009454.md) | 3.01 Delisting notice | 0001829126-26-009454 | | 2026-08-19 | 20:16 ET | [10-Q](/filings/0001104659-26-098783.md) | Quarterly report, period 2026-06-30 | 0001104659-26-098783 | | 2026-07-23 | 00:13 ET | [8-K](/filings/0001829126-26-007760.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001829126-26-007760 | | 2026-07-02 | 21:37 ET | [SCHEDULE 13D/A](/filings/0001829126-26-007224.md) | Ownership report, active investor, amended | 0001829126-26-007224 | | 2026-05-15 | 19:30 ET | [10-Q](/filings/0001104659-26-062397.md) | Quarterly report, period 2026-03-31 | 0001104659-26-062397 | | 2026-05-07 | 20:07 ET | [8-K](/filings/0001829126-26-004744.md) | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001829126-26-004744 | | 2026-04-15 | 20:03 ET | [10-K](/filings/0001104659-26-043782.md) | Annual report, period 2025-12-31 | 0001104659-26-043782 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-043782.md), filed Apr 15, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1479419 - Tickers: KALA - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.